Next Article in Journal
Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)
Next Article in Special Issue
Internet Survey of Awareness and Behavior Related to HPV Vaccination in Japan
Previous Article in Journal
Meningococcal Vaccines: Challenges and Prospects
Previous Article in Special Issue
Japanese Mothers’ Intention to HPV Vaccinate Their Daughters: How Has It Changed over Time Because of the Prolonged Suspension of the Governmental Recommendation?
Review

Efforts at COVID-19 Vaccine Development: Challenges and Successes

1
One Medical Center Drive, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
2
New Orleans East Hospital, 5620 Read Blvd, New Orleans, LA 70127, USA
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 739; https://doi.org/10.3390/vaccines8040739
Received: 23 November 2020 / Revised: 3 December 2020 / Accepted: 3 December 2020 / Published: 6 December 2020
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world. View Full-Text
Keywords: pandemics; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); COVID-19 disease; vaccines; trials; public health pandemics; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); COVID-19 disease; vaccines; trials; public health
Show Figures

Figure 1

MDPI and ACS Style

Haque, A.; Pant, A.B. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines 2020, 8, 739. https://doi.org/10.3390/vaccines8040739

AMA Style

Haque A, Pant AB. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines. 2020; 8(4):739. https://doi.org/10.3390/vaccines8040739

Chicago/Turabian Style

Haque, Azizul, and Anudeep B. Pant 2020. "Efforts at COVID-19 Vaccine Development: Challenges and Successes" Vaccines 8, no. 4: 739. https://doi.org/10.3390/vaccines8040739

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop